Vascular localization of the heparin-binding serpins antithrombin, heparin cofactor II, and protein C inhibitor

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 3, 1996, Pages 185-191

  Cooper, Scott T ^a   Neese, Laura L ^a   DiCuccio, Michael N ^b   Liles, Darla K ^a   Hoffman, Maureane ^b   Church, Frank C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endothelium; Glycosaminoglycan; Immunohistochemistry; Lactoferrin; Tissue factor pathway inhibitor

Indexed keywords

EID: 0000712096     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969600200307     Document Type: Article

References (43)

1. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481-520.
2. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
3. Novotny WF, Maffi T, Mehta RL, et al. Identification of novel heparin-releasable proteins, as well as the cytokines midkine and pleiotrophin, in human postheparin plasma. Atheroscler Thromb 1993;13:1798-1805.
4. Heeb MJ, Espana F, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 1989;73:446-54.
5. Hoogendoorn H, Nesheim ME, Giles AR. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood 1990;75:2164-71.
6. Rezaie AR, Cooper ST, Church FC, et al. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995;270:25336-9.
7. Conard J, Lecompte T, Horellou MH, et al. Antithrombin III in patients treated with subcutaneous or intravenous heparin. Thromb Res 1981;22:507-11.
8. Andersson G, Fagrell B, Holmgren K, et al. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34:333-40.
9. Francis JRB, Thomas W. Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemost 1984;52:71-4.
10. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66:59-63.
11. Toulon P, Vitoux JF, Capron L, et al. Heparin cofactor II in patients with deep venous thrombosis under heparin and oral anticoagulant therapy. Thromb Res 1988;49:497-500.
12. Tollefsen DM, Pestka CA. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 1985;66:769-74.
13. Tabernero D, Espana F, Vicente V, et al. Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment. Thromb Haemost 1990;63:380-2.
14. Chan V, Chan TK, Wang V, et al. The determination of antithrombin III by radioimmunoassay and its clinical application. Br J Hematol 1979;41:563-72.
15. Marcum JA, Atha DH, Fritze LMS, et al. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparin sulfate proteoglycan. J Biol Chem 1986;261:7507-17.
16. Carlson TH, Simon TL, Atencio AC. In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools. Blood 1985;66:13-9.
17. Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985;260:3501-5.
18. Pratt CW, Whinna HC, Church FC. A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem 1992;267:8795-801.
19. Blinder MA, Tollefsen DM. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. J Biol Chem 1990; 265:286-91.
20. Whinna HC, Blinder MA, Szewczyk M, et al. Role of lysine 173 in heparin binding to heparin cofactor II. J Biol Chem 1991;266:8129-35.
21. Evans DL, Marshall CJ, Christey PB, et al. Heparin binding site, conformational change, and activation of antithrombin. Biochemistry 1992;31:12629-42.
22. Espana F, Griffin JH. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. Thromb Res 1989;55:671-82.
23. Laurell M, Christensson A, Abrahamsson PA, et al. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 1992;89:1094-101.
24. Radtke KP, Fernandez JA, Greengard JS, et al. Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest 1994;94:2117-24.
25. Shirk RA, Elisen MGLM, Meijers JCM, et al. Role of the H helix in heparin binding to protein C inhibitor. J Biol Chem 1994;269:28690-5.
26. Hoogendoorn H, Toh CH, Nesheim M, et al. Analysis of the partitioning of endogenously generated activated protein C (APC) with its inhibitors suggests the presence of heparin-like cofactor activity for protein C inhibitor (PCI) in vivo. Circulation 1992;86:I-815.
27. Phillips JE, Cooper ST, Potter EE, et al. Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity. J Biol Chem 1994;269:16696-700.
28. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analyt Biochem 1977;15:45-52.
29. Wu HF, Lundblad RL, Church FC. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995;85:421-8.
30. Handeland GF, Abildgaard U. Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin. Thromb Res 1984;35:627-36.
31. Church FC, Hoffman MR. Heparin cofactor II and thrombin: heparin-binding proteins linking hemostasis and inflammation. Trends Cardiovasc Med 1994;4:140-6.
32. Werling RW, Zacharski LR, Kisiel W, et al. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Hemost 1993;69:366-9.
33. Mann DM, Romm E, Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Cliem 1994;269:23661-7.
34. Antonsen S, Wiggers P, Dalhoj J, et al. An enzyme-linked immunosorbent assay for plasma-lactoferrin. Concentrations in 362 healthy, adult blood donors. Scand J Clin Lab Invest 1993;53:133-44.
35. He J, Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 1995; 373:721-4.
36. Andersson LO, Borg H, Miller-Andersson M. Purification and characterization of human factor IX. Thromb Res 1975; 7:451-9.
37. Girma JP, Meyer D, Verweij CL, et al. Structure-function relationship of human von Willebrand factor. Blood 1987;70: 605-11.
38. Bockenstedt P, Greenberg JM, Handin RI. Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. J Clin Invest 1986;77:743-9.
39. Dawes J, Smith RC, Pepper DS. The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4. Thromb Res 1978;12:851-61.
40. Karlsson K, Marklund SL. Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J 1987;242:55-9.
41. Novotny WF, Palmier M, Wun TC, et al. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394-400.
42. Huttunen JK, Ehnholm C, Kinnunen PKJ, et al. An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975;63:335-47.
43. Kern PA, Martin RA, Carty J, et al. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type I hyperlipoproteinemia. J Lipid Res 1990;31:17-26.